

Victor Pantea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12033936/publications.pdf>

Version: 2024-02-01

7
papers

463
citations

1307594

7
h-index

1720034

7
g-index

7
all docs

7
docs citations

7
times ranked

411
citing authors

#	ARTICLE	IF	CITATIONS
1	HBsAg isoform dynamics during NAPI-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection. <i>Hepatology Communications</i> , 2022, 6, 1870-1880.	4.3	10
2	Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139 and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection. <i>Hepatology Communications</i> , 2021, 5, 189-202.	4.3	62
3	Benefit of transaminase elevations in establishing functional cure of HBV infection during napi-based combination therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 817-825.	2.0	10
4	Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAPI-Based Therapy. <i>Hepatology Communications</i> , 2021, 5, 1873-1887.	4.3	12
5	Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. <i>Scientific Reports</i> , 2020, 10, 7837.	3.3	24
6	Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy. <i>Gastroenterology</i> , 2020, 158, 2180-2194.	1.3	154
7	Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naïve patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 877-889.	8.1	191